GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Other Current Payables

Psyence Biomedical (Psyence Biomedical) Other Current Payables : $0.00 Mil (As of Mar. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Other Current Payables?

Psyence Biomedical's Other Current Payables for the quarter that ended in Mar. 2023 was $0.00 Mil.


Psyence Biomedical Other Current Payables Historical Data

The historical data trend for Psyence Biomedical's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Other Current Payables Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23
Other Current Payables
- - -

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Mar23
Other Current Payables - - -

Psyence Biomedical Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


Psyence Biomedical Other Current Payables Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


Psyence Biomedical (Psyence Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines